SCHEMBL23979071

SCHEMBL23979071

O=C(Cc1ccccc1)Nc1ccc(Cl)c(C(=O)N[C@@H](CNC(=O)NCc2ccccc2O)C(=O)O)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
ITGB1 P05556 2/20 0.39
ITGAV P06756 2/20 0.39
ITGA5 P08648 2/20 0.39
ITGA4 P13612 2/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
ITGAL P20701 3/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26104460 1.00 ALDH1A1 (0.39) ALDH1A1HPGDMEN1KMT2AITGB1
SCHEMBL30279338 1.00 ALDH1A1 (0.39) ALDH1A1HPGDMEN1KMT2AITGB1
SCHEMBL30279382 0.93 KCNQ2 (0.39) ALDH1A1HPGDMEN1KMT2AITGB1
SCHEMBL23978590 0.93 KCNQ2 (0.39) ALDH1A1HPGDMEN1KMT2AITGB1
SCHEMBL23978614 0.93 KCNQ2 (0.39) ALDH1A1HPGDMEN1KMT2AITGB1
SCHEMBL26476406 0.92 ITGB1 (0.38) ALDH1A1ITGB1ITGAVITGA5ITGA4
SCHEMBL23979054 0.82 PPIA (0.40) ALDH1A1ITGB1ITGAVITGA5ITGA4
SCHEMBL30083822 0.82 PPIA (0.40) ALDH1A1ITGB1ITGAVITGA5ITGA4
SCHEMBL30279434 0.82 PPIA (0.40) ALDH1A1ITGB1ITGAVITGA5ITGA4
SCHEMBL26107303 0.82 PPIA (0.40) ALDH1A1ITGB1ITGAVITGA5ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
WO-2021222789-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 ALDH1A1 399/4885HPGD 2579/4885MEN1 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.